Literature DB >> 22046087

Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma.

Shilpa Jain1, Shashideep Singhal, Franto Francis, Cristina Hajdu, Jin-Hua Wang, Arief Suriawinata, Yin-Quan Wang, Miao Zhang, Elizabeth H Weinshel, Fritz Francois, Zhi-Heng Pei, Peng Lee, Ru-Liang Xu.   

Abstract

AIM: To determine the expression and clinical significance of transcriptional intermediary factor 1 gamma (TIF1γ), Smad4 and transforming growth factor-beta (TGFβR) across a spectrum representing colorectal cancer (CRC) development.
METHODS: Tissue microarrays were prepared from archival paraffin embedded tissue, including 51 colorectal carcinomas, 25 tubular adenomas (TA) and 26 HPs, each with matched normal colonic epithelium. Immunohistochemistry was performed using antibodies against TIF1γ, Smad4 and TGFβRII. The levels of expression were scored semi-quantitatively (score 0-3 or loss and retention for Smad4).
RESULTS: Overexpression of TIF1γ was detected in 5/26 (19%) HP; however, it was seen in a significantly higher proportion of neoplasms, 15/25 (60%) TAs and 24/51 (47%) CRCs (P < 0.05). Normal colonic mucosa, HP, and TAs showed strong Smad4 expression, while its expression was absent in 22/51 (43%) CRCs. Overexpression of TGFβRII was more commonly seen in neoplasms, 13/25 (52%) TAs and 29/51 (57%) CRCs compared to 9/26 (35%) HP (P < 0.05). Furthermore, there was a correlation between TIF1γ overexpression and Smad4 loss in CRC (Kendall tau rank correlation value = 0.35, P < 0.05). The levels of TIF1γ overexpression were significantly higher in stage III than in stage I and II CRC (P < 0.05).
CONCLUSION: The findings suggest that over-expression of TIF1γ occurs in early stages of colorectal carcinogenesis, is inversely related with Smad4 loss, and may be a prognostic indicator for poor outcome.

Entities:  

Keywords:  Colorectal cancer; Smad4; Transcriptional intermediary factor 1 gamma; Transforming growth factor-beta signaling pathway

Mesh:

Substances:

Year:  2011        PMID: 22046087      PMCID: PMC3199557          DOI: 10.3748/wjg.v17.i35.3994

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  TGF-beta signaling in colon cancer cells.

Authors:  Fazhi Li; Yanna Cao; Courtney M Townsend; Tien C Ko
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

2.  Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer.

Authors:  Y Guo; S C Jacobs; N Kyprianou
Journal:  Int J Cancer       Date:  1997-05-16       Impact factor: 7.396

3.  Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.

Authors:  Y Guo; N Kyprianou
Journal:  Cell Growth Differ       Date:  1998-02

Review 4.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis.

Authors:  M Miyaki; T Iijima; M Konishi; K Sakai; A Ishii; M Yasuno; T Hishima; M Koike; N Shitara; T Iwama; J Utsunomiya; T Kuroki; T Mori
Journal:  Oncogene       Date:  1999-05-20       Impact factor: 9.867

7.  Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas.

Authors:  H Gobbi; C L Arteaga; R A Jensen; J F Simpson; W D Dupont; S J Olson; P A Schuyler; W D Plummer; D L Page
Journal:  Histopathology       Date:  2000-02       Impact factor: 5.087

Review 8.  Genetic and epigenetic alterations in colon cancer.

Authors:  William M Grady; Sanford D Markowitz
Journal:  Annu Rev Genomics Hum Genet       Date:  2002-04-15       Impact factor: 8.929

9.  Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas.

Authors:  David F Vincent; Kai-Ping Yan; Isabelle Treilleux; Fabien Gay; Vanessa Arfi; Bastien Kaniewski; Bastien Kaniewsky; Julien C Marie; Florian Lepinasse; Sylvie Martel; Sophie Goddard-Leon; Juan L Iovanna; Pierre Dubus; Stéphane Garcia; Alain Puisieux; Ruth Rimokh; Nabeel Bardeesy; Jean-Yves Scoazec; Régine Losson; Laurent Bartholin
Journal:  PLoS Genet       Date:  2009-07-24       Impact factor: 5.917

10.  Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase.

Authors:  Sirio Dupont; Luca Zacchigna; Michelangelo Cordenonsi; Sandra Soligo; Maddalena Adorno; Massimo Rugge; Stefano Piccolo
Journal:  Cell       Date:  2005-04-08       Impact factor: 41.582

View more
  14 in total

1.  Imbalanced expression of Tif1γ inhibits pancreatic ductal epithelial cell growth.

Authors:  Martin Ligr; Xinyu Wu; Garrett Daniels; David Zhang; Huamin Wang; Cristina Hajdu; Jinhua Wang; Ruimin Pan; Zhiheng Pei; Lanjing Zhang; Marcovalerio Melis; Matthew R Pincus; John K Saunders; Peng Lee; Ruliang Xu
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

2.  Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.

Authors:  Payam Mohassel; Paul Rosen; Livia Casciola-Rosen; Katherine Pak; Andrew L Mammen
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

3.  TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Authors:  Loay Kassem; Mathieu Deygas; Laurent Fattet; Jonathan Lopez; Thibaut Goulvent; Emilie Lavergne; Sylvie Chabaud; Nicolas Carrabin; Nicolas Chopin; Thomas Bachelot; Germain Gillet; Isabelle Treilleux; Ruth Rimokh
Journal:  BMC Cancer       Date:  2015-06-04       Impact factor: 4.430

Review 4.  Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer.

Authors:  Audrey Aussy; Olivier Boyer; Nadège Cordel
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

5.  Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.

Authors:  Ayan Chanda; Angela Chan; Lili Deng; Elizabeth N Kornaga; Emeka K Enwere; Donald G Morris; Shirin Bonni
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

6.  The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.

Authors:  Lili Yu; Xiaoqing Lin; Liangming Zhang; Qingwei Wu; Songgao Zhang; Dunyan Chen; Xiaojie Pan; Yi Huang
Journal:  Int J Med Sci       Date:  2020-06-21       Impact factor: 3.738

7.  Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an "autoimmune tumor marker": A case report.

Authors:  Kohei Karino; Yuichiro Fujieda; Takuya Kawamura; Nobuya Abe; Shuhei Shimoyama; Michihito Kono; Masaru Kato; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 8.  The Roles of TIF1γ in Cancer.

Authors:  Chengpeng Yu; Zeyang Ding; Huifang Liang; Bixiang Zhang; Xiaoping Chen
Journal:  Front Oncol       Date:  2019-10-02       Impact factor: 6.244

9.  Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma.

Authors:  Seung-Yeon Yoo; Ji-Ae Lee; Yunjoo Shin; Nam-Yun Cho; Jeong Mo Bae; Gyeong Hoon Kang
Journal:  J Pathol Transl Med       Date:  2019-06-24

Review 10.  TIF1 Proteins in Genome Stability and Cancer.

Authors:  Roisin M McAvera; Lisa J Crawford
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.